CAJ | 학술논문

Apremilast是一种口服的小分子磷酸二酯酶4 ( PDE-4 )抑制剂,已被FDA批准用于治疗成人银屑病关节炎和中至重度斑块型银屑病. 大多数患者口服Apremilast的推荐剂量是30 mg/次,2次/d,与或不与食物同服. Apremilast一般耐受性良好,无严重不良反应报道. 本文对Apremilast的药理活性、药代动力学、剂量滴定、临床研究、不良反应等方面进行综述.
Apremilast시일충구복적소분자린산이지매4 ( PDE-4 )억제제,이피FDA비준용우치료성인은설병관절염화중지중도반괴형은설병. 대다수환자구복Apremilast적추천제량시30 mg/차,2차/d,여혹불여식물동복. Apremilast일반내수성량호,무엄중불량반응보도. 본문대Apremilast적약리활성、약대동역학、제량적정、림상연구、불량반응등방면진행종술.
Apremilast is an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase ( PDE-4),the global approval of apremilast was granted by the US FDA for the treatment of active psoriatic arthritis and plaque psoriasis in adults. The recommended dosage of oral apremilast for most patients is 30 mg twice daily (bid), taken with or without food. Apremilast is generally well tolerated without serious adverse reaction. The pharmacological activity,pharmacokinetics,dosage,clinical research,adverse events and other aspects of apremilast are summarized in the article.